Inclusion Criteria:  Age range from 40 to 75, regardless of ethnic group or gender; Meeting the criteria for clinically established PD (2015) by Movement Disorder Association（MDS）; duration < 5 years; Hoehn-Yahr stage ≤ 3; Before enrollment, patients should take a stable dose of dopamine-based therapies drugs; No obvious visual or hearing impairment; More than 9 years of education; Patients understand and comply with the study procedure, and are able to complete all tests and examinations required by the program. Sign the informed consent.  Exclusion Criteria:  The total score of Mini-Mental State Examination (MMSE) ≤ 25 points; Patients who have received globus pallidotomy, thalamotomy, deep brain stimulation (DBS), or stem cell therapy; Other causes of parkinsonism: medications (e.g., metoclopramide, flunarizine), metabolic neurogenetic disorders (e.g., Wilson's disease), encephalitis, cerebrovascular diseases, or degenerative disorders (e.g., progressive supranuclear palsy); Central nervous system diseases (including stroke, optic neuromyelitis, Parkinson's disease, epilepsy, etc.); Have liver, kidney function insufficiency; Unstable or severe diseases of the heart, lung, liver, kidney and hematopoietic system according to the judgment of the researchers; Participated in other clinical trials within 3 months before screening visit; Other conditions are unsuitable for participating in this study according to the judgement of researchers.